Meldinga vil ikke komme før den har fått oncos, nå har pasienten bare blitt tatt opp uten første oncosdose etter det jeg leser i farta. Sotio meldte vel oppstart for noen dager siden: http://www.sotio.com/news-publications/news/sotio-starts-phase-i-ii-trial-of-dcvac-in-combination-with-oncos-102-the-targovax-adenovirus-based-immunotherapy
1 Like
Da starter ASCO opp idag 
4 dager I Chicago , og i tillegg skal de også på Jefferies 2018 Global Healthcare Cenference I New York resten av neste uke .
Den var ny for meg i kalenderen dems
Det er nok morro for Targovax og kunne snakke litt om 2-års overlevelsen på TG01 ! Kan jo håpe at interessen tar seg opp og at større seriøse investorer får lyst på en bit av kaka
Gjør som Targovax og drar til USA i helga sjæl 
4 Likes
De skal ikke presentere så det blir vel dere til å gå rundt og stråle seg i lyset av egne resultater. Er nok noen som vil snakke med TRVX der borte 
1 Like
Det vet jeg , men blir nok litt prat rundt det uansett ja 
Tror ikke man skal undervurdere betydningen av å være tilstede på slike konferanser, selv om man nødvendigvis ikke presenterer noe alltid. Her møtes nøkkelpersonell innen det internasjonale farmasimiljøet og her pleies og utvides nettverket med nyttige kontakter. Resultatene av slik deltagelse kan vise seg meget raskt. Spesielt for selskaper som TRVX som etterhvert har mye spennende å vise til samt mange pågående tester.
3 Likes
4 Likes
Targovax to Present at Jefferies 2018 Global Healthcare Conference
Oslo, Norway, 4 June 2018: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that CMO Magnus Jäderberg will present a company overview at the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, 2018 at 16:00 EDT in New York, NY.
Presentation slides will be available following the event at www.targovax.com/Investors.
For information about the conference, visit https://www.jefferies.com/OurFirm/Conferences/325/382For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: [email protected]
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: [email protected]
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: [email protected] .
About Targovax
Arming the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
The Company’s development pipeline is based on two novel proprietary platforms:
The first platform, ONCOS, uses oncolytic viruses as potential multi-target, neo-antigen therapeutic cancer vaccines. ONCOS uses an adenovirus that has been engineered to be an immune activator that selectively targets cancer cells. In phase I trials it has demonstrated immune activation at lesional level which was associated with clinical benefit. In an ongoing phase I trial in advanced melanoma we expect important proof of concept data for checkpoint inhibitor refractory patients.
The second platform, TG, are neo-antigen cancer vaccines designed to specifically treat tumors that express mutated forms of RAS. Mutations to the RAS protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations. The TG platform’s therapeutic potential stems from its ability to enable the patient’s immune system to identify and destroy tumors bearing any RAS mutations. In early 2017, key proof of concept data for the TG platform from a clinical trial of TG01 in resected pancreatic cancer patients showed encouraging overall survival and will give guidance for the future clinical development of this platform.
Targovax’s development pipeline has three novel therapeutic candidates in clinical development covering six indications.
Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost-effective manner. Additionally, Targovax has other products in early stages of development.
This release was sent by Targovax
1 Like
Fint å lade opp til presentasjon med eit saftig 4,5% fall hvertfall!
1 Like
Targovax to Present at Jefferies 2018 Global Healthcare Conference
Oslo, Norway, 4 June 2018: Targovax ASA (“Targovax” or “the Company”; OSE:
TRVX), a clinical stage company focused on developing immuno-oncology therapies
to target solid tumors, today announces that CMO Magnus Jäderberg will present a
company overview at the Jefferies 2018 Global Healthcare Conference on
Wednesday, June 6, 2018 at 16:00 EDT in New York, NY.Presentation slides will be available following the event at
www.targovax.com/Investors.For information about the conference, visit
https://www.jefferies.com/OurFirm/Conferences/325/382For further information,
please contact:Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: [email protected]Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: [email protected]Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: [email protected] .About Targovax
Arming the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage company focused on developing and
commercializing novel immuno-oncology therapies to target, primarily,
treatment-resistant solid tumors. Immuno-oncology is currently one of the
fastest growing therapeutic fields in medicine.The Company’s development pipeline is based on two novel proprietary platforms:
The first platform, ONCOS, uses oncolytic viruses as potential multi-target,
neo-antigen therapeutic cancer vaccines. ONCOS uses an adenovirus that has been
engineered to be an immune activator that selectively targets cancer cells. In
phase I trials it has demonstrated immune activation at lesional level which was
associated with clinical benefit. In an ongoing phase I trial in advanced
melanoma we expect important proof of concept data for checkpoint inhibitor
refractory patients.The second platform, TG, are neo-antigen cancer vaccines designed to
specifically treat tumors that express mutated forms of RAS. Mutations to the
RAS protein are common in many cancers and are known to drive aggressive disease
progression and treatment resistance. There is a high unmet medical need for
therapies that are effective against tumors that express these mutations. The TG
platform’s therapeutic potential stems from its ability to enable the patient’s
immune system to identify and destroy tumors bearing any RAS mutations. In early
2017, key proof of concept data for the TG platform from a clinical trial of
TG01 in resected pancreatic cancer patients showed encouraging overall survival
and will give guidance for the future clinical development of this platform.Targovax’s development pipeline has three novel therapeutic candidates in
clinical development covering six indications.Both platforms are protected by an extensive portfolio of IP and know-how and
have the potential to yield multiple product candidates in a cost-effective
manner. Additionally, Targovax has other products in early stages of
development.Ekstern link: http://www.newsweb.no/index.jsp?messageId=452872
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20180604.OBI.20180604S31
Venter på immundata fra TG01
– Det er en milepæl at 13 av 19 pasienter var i live etter to år. Det skal litt til for at dette er tilfeldigheter, men nå blir det viktig for oss å få immundata som kan vise en sammenheng mellom immunaktivering og overlevelse. Så de virkelige interessante dataene ligger foran oss, sier administrerende direktør i Targovax, Øystein Soug til Dagens Medisin. Han håper dataene kan presenteres på den amerikanske kreftkongressen ASCO i juni.
1 Like
Har tradet Targovax noe tidligere, men kjøpte i dag mine første aksjer for å bli sittende.
Overlevelsestallene fra TG01-studiet overbeviste meg. At 2-årsoverlevelsen er økt til 72% i cohort 2 sammenlignet med 68% i cohort 1 er fint, men spesielt liker jeg at median som enda ikke er nådd i cohort 2 blir bedre enn median i cohort 1 - og allerede er 5,8 måneder bedre enn ESPAC4.
ONCOS som virker ha verdi hos analytikerne har imidlertid ikke overbevist meg. Dog virker risk/reward være meget lovende når TRVX er verdsatt til 940 millioner. Jeg er vel en av få aksjonærer som håper på en nedtur såpass jeg får lastet litt mer til en rimelig penge 
2 Likes
Det er riktig. Og Targovax går videre med stadig mer oppløftende data 
77% i cohort 2, 72% totalt 
2 Likes
Du har selvsagt helt rett. Virkelig lovende tall
Jepp! Og da er det i tillegg enda flere R1 - pasienter (R1=mikroskop synlig tumorceller i området rundt der tumor er fjernet) enn det er i SoC Espac-4 studien.
R1 - pasienter har kortere forventet levetid enn R0 (all synlig tumor fjernet), i ESPAC-4 studien rundt 22 måneder. Samlet her var mOS ~27 mnd.
Når cohort II TG01 enda ikke har nådd mOS så lukter det svidd. Cohort I og II hadde vel nesten 34 mnd mOS ved tidspunkt melding. Cohort II vil altså knuse dagens SoC ned i støvlene 
4 Likes
2 Likes
Elendig utvikling here siste dagene, lite forhåpninger til presentasjon i morgen hvertfall…
Det er vel en investorkonferanse primært.
Forventes der flere data her i Q2?